About MiMedx
MiMedx® is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to provide physicians with products and tissues to help the body heal itself.
We process human placental tissue utilizing our proprietary PURION® process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization.
Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be the leader in placental based products with over 40 scientific and clinical publications contained in our Compendium, six completed and published Randomized Controlled Trials (RCTs), and 30 ongoing clinical studies. MiMedx has over 45 placental tissue issued and allowed patents on our products and technologies, with over 90 pending applications. We have continued to demonstrate this leadership by publishing a Primer to educate the medical community on the regenerative aspects of amniotic membrane allografts.
MiMedx has supplied over 1 million placental tissue-based allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
We process human placental tissue utilizing our proprietary PURION® process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization.
Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be the leader in placental based products with over 40 scientific and clinical publications contained in our Compendium, six completed and published Randomized Controlled Trials (RCTs), and 30 ongoing clinical studies. MiMedx has over 45 placental tissue issued and allowed patents on our products and technologies, with over 90 pending applications. We have continued to demonstrate this leadership by publishing a Primer to educate the medical community on the regenerative aspects of amniotic membrane allografts.
MiMedx has supplied over 1 million placental tissue-based allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
FAQs
- When was MiMedx founded?
- MiMedx was founded in 2008.
- Who is the CEO of MiMedx?
- Timothy R Wright is the CEO.
- What industries or markets does MiMedx operate in?
- MiMedx operates in the following markets: Biotechnology and Biopharmaceutical.
- How many employees does MiMedx have?
- MiMedx has 501-1000 employees.
- Where does MiMedx have employees?
- MiMedx has employees in United States.
- Does MiMedx support remote work or working from home?
- Yes, MiMedx is a remote-friendly company.
- What employee benefits does MiMedx offer?
- MiMedx provides 4 benefits to their employees.
- Does MiMedx offer a four-day work week?
- No, MiMedx does not offer a four-day work week.
- What is MiMedx's tech stack?
- MiMedx has 26 technologies in their tech stack.
- What is MiMedx's website?
- MiMedx's website is mimedx.com.
United States
